Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis

Main Article Content

Howard Sofen
Stephen Tyring
Sandra Marchese Johnson
Scott Guenthner
Patrick Shannon
Philip M. Brown
Katherine Tillman
Nancy Fitzgerald
Brandon Kirsch
Anna Tallman
a:1:{s:5:"en_US";s:9:"Dermavant";}

Keywords

plaque psoriasis, intertriginous psoriasis, inverse psoriasis, tapinarof cream 1% once daily, patient-reported outcomes, PROs, DLQI, PP-NRS, treatment satisfaction, AhR agonist

References

1. Hong JJ, et al. Dermatol Ther (Heidelb). 2021;11:883–844.

2. Merola JF, et al. Dermatol Ther. 2018;31(3):e12589.

3. Yasir M, et al. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
https://www.ncbi.nlm.nih.gov/books/NBK531462/. Accessed September 2023.

4. Goh MS, et al. Med J Aust. 2022;216:587–593.

5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed September 2023. 6. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229.

7. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

8. Sofen H, et al. Poster at Fall Clinical Dermatology Conference, October 19–22, 2023, Las Vegas, NV.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.242

Article Details

How to Cite
[1]
Sofen, H., Tyring, S., Johnson, S.M., Guenthner, S., Shannon, P., Brown, P.M., Tillman, K., Fitzgerald, N., Kirsch, B. and Tallman, A. 2023. Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s242. DOI:https://doi.org/10.25251/skin.7.supp.242.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>